(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -27.82% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Aclaris Therapeutics's revenue in 2025 is $17,778,000.On average, 5 Wall Street analysts forecast ACRS's revenue for 2025 to be $710,758,053, with the lowest ACRS revenue forecast at $552,234,319, and the highest ACRS revenue forecast at $1,039,499,894. On average, 5 Wall Street analysts forecast ACRS's revenue for 2026 to be $676,108,056, with the lowest ACRS revenue forecast at $97,453,115, and the highest ACRS revenue forecast at $1,082,812,390.
In 2027, ACRS is forecast to generate $751,471,799 in revenue, with the lowest revenue forecast at $630,196,811 and the highest revenue forecast at $963,703,027.